Bendamustine is used in combination with rituximab (BR) to treat indolent non-Hodgkin lymphomas (iNHL) and mantle cell lymphoma (MCL). The variability in treatment efficacy and toxicity could be related to single nucleotide polymorphisms (SNPs) in immune response genes. We would like to show a correlation between SNPs and treatment outcome in iNHL and MCL patients receiving BR. We investigated some SNPs that had already been associated with NHL outcome. Samples were genotyped for the IL2 (rs2069762), IL10 (rs1800890, rs10494879), VEGFA (rs3025039), IL8 (rs4073), CFH (rs1065489) and MTHFR (rs1801131) SNPs by allelic discrimination assays. We enrolled 70 patients that received rituximab 375 mg/m 2 and bendamustine 90 mg/m 2 every 28 days, both as first-line treatment and ≥ second-line regimens. Overall response rate was 97Á1% (complete response [CR] rate 73Á9%). Treatment toxicity included grade 3-4 neutropenia (24/70 patients), infections (21/70 patients; 1/70 grade 3), skin rash (26/70 patients; 2/70 grade 3). After a median follow-up of 24 months we did find any correlation between the analysed SNPs, CR rate and PFS. However, we demonstrated an association between the SNP in IL2 (rs2069762) and the onset of skin rash (P = 0Á0001). Our study suggests a role for cytokine SNPs in bendamustine-related toxicity, which could represent a promising research field.
Indolent non-Hodgkin lymphomas (iNHL) are characterized by a slow rate of growth, which allows long-term survival, in most cases. iNHL are chemo-and radio-sensitive and have a marked propensity to relapse, resulting in the need for multiple therapies over a period of years (Swerdlow et al, 2008 (Swerdlow et al, , 2016 . Histological iNHL subtypes include follicular lymphoma (FL), lymphoplasmacytic lymphoma (LPL), marginal zone lymphoma (MZL) and lymphocytic lymphoma (SLL). The main treatment goal is disease control and maintaining quality of life rather than disease eradication. Chemoimmunotherapy is required for active/progressive disease; to achieve a complete response (CR), we can use anthracyclinecontaining regimens, alkylating agents and/or purine analogues, such as fludarabine or bendamustine in combination with the monoclonal antibody rituximab (Dreyling et al, 2013; Tarella et al, 2015) .
Commonly used prognostic scores for FL are the FL International Prognostic Index (FLIPI) and FLIPI2; for mucosaassociated lymphoid tissue (MALT) lymphoma patients the MALT IPI score was recently validated (Solal-C eligny et al, 2004; Federico et al, 2009; Thieblemont et al, 2017) . However, these scores are mainly focused on tumour burden and don't permit an optimal stratification for all patients.
MCL is an uncommon malignancy with the molecular hallmark represented by the t(11;14)(q13q32) translocation (Cheah et al, 2016; Dreyling et al, 2017) . There are 2 variants: SOX11 positive and IGHV unmutated cases have a very aggressive behaviour, while the less frequent variant with SOX11 negative and IGHV mutated genes is more indolent and associated with better prognosis (Vegliante et al, 2013) . The MCL IPI (MIPI) has an important prognostic role; Ki67 ≥30%, in addition to MIPI was significantly associated with lower progression-free survival (PFS) (Cheah et al, 2016; Dreyling et al, 2017) . High-dose cytarabine and autologous stem cell transplantation (ASCT) are not feasible for elderly or unfit patients. In this subgroup, the combination of rituximab with bendamustine and cytarabine (R-BAC) has demonstrated high efficacy and manageable toxicity, even if cytarabine is not well tolerated (Visco et al, 2017) .
Bendamustine is a cytotoxic drug whose chemical structure combines the characteristics of both an alkylating agent and a purine analogue; it represents an important weapon against iNHL, MCL, chronic lymphocytic leukaemia (CLL), multiple myeloma and Hodgkin lymphoma (Hoy, 2012; Rummel et al, 2013; Flinn et al, 2014; Eichhorst et al, 2016) . Skin rash has been frequently observed, especially in patients taking concomitant medications such as thrimethoprim-sulfamethoxazole and allopurinol (Hoy, 2012; Cheson et al, 2016) .
Several trials showed high efficacy and manageable toxicity of bendamustine in relapsed/refractory iNHL and MCL patients, both as monotherapy and in combination with rituximab (BR) (Czuczman et al, 2015; Rummel et al, 2016) . The efficacy and safety of BR as first-line treatment for iNHL and MCL patients were confirmed in several phase II trials and in two randomized studies, i.e., the StiL NHL-1 and the BRIGHT study, which aimed to investigate the non-inferiority of BR compared to rituximab with cyclophosphamide, vincristine, prednisone with or without doxorubicin (R-CHOP/R-CVP scheme) (Rummel et al, 2013; Flinn et al, 2014; Luminari et al, 2016; Mondello et al, 2016) . A warning about late infections, lymphocytopenia and secondary malignancies was recently reported in the long-term results of these trials, even if other studies are reassuring with regard to BR safety (Olszewski et al, 2018) .
Many iNHL patients finally relapse and a wide variability in treatment efficacy and safety has been reported in many studies. An interesting hypothesis speculates that this variability could be due, at least in part, to genetic factors of the host, such as germline single nucleotide polymorphisms (SNPs) in genes that affect drug disposition, pharmacodynamics and the components of reactive microenvironment (Johnson et al, 2014) . Along this concept, there is a wellestablished cytokine-mediated connection between innate immunity, inflammation and cancer (Lin & Karin, 2007) . Commonly reported genetic variants in cytokine and other immune genes were linked to an increased risk of developing NHL compared to the general population and some of them were associated with prognosis in cohort studies (Cerhan et al, 2007; Kube et al, 2008; Wang et al, 2009; AschebrookKilfoy et al, 2012; Charbonneau et al, 2012; Gibson et al, 2012; Wr obel et al, 2013; Baecklund et al, 2014; Gao et al, 2014; Guti errez-C ıvicos et al, 2016 Guti errez-C ıvicos et al, , 2017 . The pivotal paper by Cerhan et al (2007) showed SNPs in IL2 (a T-helper type 1 [Th1] cytokine that plays an important role in lymphoid activation and proliferation), CXCL8 (previously termed IL8, produced by a variety of cells at inflammatory sites, and stimulates neutrophils degranulation and chemotaxis), IL12B and IL1RN were strong survival predictors. Subsequent studies confirmed that genetic variants in inflammatory and immune response genes (such as IL10) and in angiogenic factors (such as VEGFA) could influence clinical outcome and side effects (Kube et al, 2008; Wr obel et al, 2013) . On this background, our study aimed to show a possible correlation between SNPs, treatment efficacy and safety in iNHL and MCL patients receiving the BR regimen.
Patients and methods

Study population
In this single-centre study we analysed a series of 70 consecutive iNHL or MCL patients diagnosed at our Institution and receiving BR as first-line treatment or as ≥ second-line regimen from 2014 to 2017. Diagnosis was made according to World Health Organization (WHO) 2008 classification (Swerdlow et al, 2008) . We included in the study all iNHL histological subtypes and MCL patients not eligible for highdose therapy; gastric MALT lymphoma patients were negative for Helicobacter pylori or with histological progressive disease or persistent disease more than 12 months after successful Helicobacter pylori eradication. All patients signed written informed consent in accordance with Institutional Review Board and the Declaration of Helsinki. At the pretreatment evaluation, physical examination, complete blood cell count, renal and liver function, lactate dehydrogenase (LDH) and b2-microglobulin (b2M), human immunodeficiency virus (HIV), hepatitis B and C virus (HBV, HCV) markers, serum immunofixation, computed tomography (CT) scan of the neck, chest, abdomen and pelvis and bone marrow biopsy were performed in all patients, as detailed by national guidelines (Tarella et al, 2015) . Diagnosis was made by esophagogastroduodenoscopy with multiple biopsies for gastric MALT lymphoma cases. Ann Arbor disease was used and the Lugano modification was preferred for gastric MALT lymphomas (Rohatiner et al, 1994) .
Treatment regimen and concomitant medications
The treatment regimen consisted of rituximab 375 mg/m 2 intravenously on day 1 and bendamustine 90 mg/m 2 on days 2-3 every 28 days for up to 6 cycles, providing that haematological recovery (neutrophil count at least 1Á5 9 10 9 /l and platelet count at least 100 9 10 9 /l) had occurred. FL patients achieving at least a partial response (PR) received maintenance therapy with rituximab every 2 months for 2 years. Intravenous hydrocortisone (200 mg), clorfenamine (10 mg) and paracetamol (500 mg) were given before the first rituximab administration; if well tolerated, hydrocortisone was not given before subsequent courses. Since 2015, FL patients received subcutaneous rituximab from the second or third administration if no adverse reactions occurred during the first intravenous course. Antimicrobial prophylaxis for Pneumocystis jiroveci pneumonia, with Trimethoprim-Sulfamethoxazole (160/800 mg twice a day, two times a week) from treatment start up to 6 months after therapy; granulocyte colony-stimulating factor (G-CSF) and levofloxacin (500 mg tablet a day) were permitted as concomitant medications for patients who developed grade 3 or 4 neutropenia. HBV-positive patients received lamivudine prophylaxis from treatment start to at least 12 months after therapy.
Response assessment and toxicity
Response assessment was made after the Cycle 4 and at least 4 weeks after the end of treatment according to the Lugano classification criteria for NHL (Cheson et al, 2014) . All patients received a final evaluation with a CT scan; CT/positron-emission tomography (PET) was performed in patients with PET-avid NHL (FL and MCL) using the Deauville 5-point scale. Bone marrow biopsy was undertaken if it was positive at baseline. Esophagogastroduodenoscopy was repeated in gastric MALT lymphoma cases. During the follow-up period, CT scans were performed at 6, 12 and 24 months; gastric MALT lymphoma cases received endoscopy yearly until the fifth year, thereafter only clinical follow-up was continued. Overall treatment toxicity was assessed according to the National Cancer Institute (NCI) Common Terminology Criteria of Adverse Events (CTCAE) v4.0 (https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf) after each course of therapy.
Genotyping analysis
The biological part of the study includes the extraction of genomic DNA and genetic analyses. After centrifugation of peripheral blood samples at 2000g, the buffy coat was isolated and then genomic DNA was extracted. We investigated some SNPs already associated with treatment outcome in NHL cases. The minor allele frequency (MAF) was determined according to the 1000 Genome study (ftp://ftp.1000genomes.ebi. ac.uk/vol1/ftp/data_collections/1000_genomes_project/), it is defined as the ratio between the frequency of the rarer and the most common variant of a given SNP. The study of MAF allows monomorphic SNPs (MAF <5%) to be distinguished from polymorphic ones (MAF ≥5%). A MAF less than 5% generally indicates errors in sequencing or extremely rare polymorphisms. Genomic DNA was extracted from peripheral blood EDTA samples using silica membranes (DSP DNA Blood Kit; Qiagen, Hilden, Germany), following the instructions of the manufacturer. All samples were genotyped for the IL2 (rs2069762), VEGFA (rs3025039), CFH (rs1065489), IL10 (rs1800890, rs10494879), CXCL8 (rs4073) and MTHFR (rs1801131) SNPs by allelic discrimination assays using the appropriate TaqMan SNP Genotyping Assays (Applied Biosystems, Foster City, CA, USA) containing forward and reverse primers and allele-specific Minor Groove Binder (MGB) probes. PCR amplification was carried out in a reaction volume of 25 ll that contained 12Á5 ll of TaqMan Genotyping Master Mix (Applied Biosystems), 900 nmol/l of each primer, 200 nmol/l of each probe and 50 ng of genomic DNA. PCR was performed on a Corbett Rotor gene 6000 system (Explera Srl, Jesi, Italy).
The allelic discrimination analysis of the SNPs was performed by using the Rotor-Gene 6000 software. As the wild type-specific probe is labelled with 2 0 -chloro-7 0 phenyl-1,4-dichloro-6-carboxyfluorescein (VIC) and the mutant-specific probe is labelled with carboxyfluorescein (FAM), the different genotypes were linked to the proper channels: wild type genotype (yellow channel), mutant genotype (green) and the heterozygous genotype (both yellow and green channels). The discrimination threshold line was then set above the background signals of the positive controls. Using these settings, 3 different results can be obtained: wild type homozygous (only allele 1): the VIC fluorescence is high, while the FAM (mutant-allele 2) one is lower; mutant homozygous (only allele 2): the FAM fluorescence is high, while the VIC (wild type-allele 1) one is lower; heterozygous (both allele 1 and allele 2): both VIC and FAM fluorescence is high.
Statystical analysis
In this single arm, single-centre study, PFs was the primary end-point and the secondary end-points were overall response rate (ORR), CR rate, treatment toxicity and overall survival (OS). Patients' characteristics were analysed with descriptive statistics. Categorical variables were analysed using Chi-square or Fisher's exact test; Fisher's exact test was preferred for small sample size, when the expected frequency was less than 5. Three-way tests were undertaken using the Freeman-Halton extension of the Fisher's exact probability test with 2 9 3 contingency tables. The distribution of IL2 genotypes according to histology and onset of skin rash was analysed by Forest plot including odds ratios (OR) and 95% confidence intervals (CIs) using a logarithmic scale to determine if the magnitude of the effect was consistent across groups. PFS was defined as the time from Day 1 of treatment until disease progression, relapse, death for any cause or last follow-up (censored); OS was defined as the time from Day 1 of treatment until death for any cause. Patients with a follow-up of at least 6 months were considered to be evaluable for survival analysis; patients without any events but with a follow-up <6 months were excluded from survival analysis. Survival curves were assessed using Kaplan and Meier plots and log rank test for significant associations; a P value <0Á05 was interpreted as statistically significant. MedCalc, version 
Results
Patients' characteristics
A cohort of 70 consecutive cases with iNHL and MCL not eligible for intensive therapy were treated with the BR regimen; patients' characteristics are shown in Table I . BR was administered as first-line treatment or ≥ second regimen in 53 and 17 cases, respectively. All patients were evaluable for safety, 1 patient was lost at follow-up and was not evaluable for response, 61/70 were evaluable for survival analysis. Median age was 69Á5 years (range 38-87 years), male/female distribution was 42/28. Out of 70 patients, 28 were diagnosed with MZL, 22 with FL, 8 with LPL, 8 with MCL and 4 with SLL. Ann Arbor stage was I in 7/70 patients, II in 7/70 patients, III in 10 patients and IV in 46/70 patients. All cases with stage I disease were gastric MALT lymphomas; in this subgroup at our Institution we prefer to administer BR rather than radiotherapy. LDH and b2M were elevated in 26/70 and 63/70 cases, respectively; bone marrow evaluation was positive in 42/70 cases. Seven out of 70 presented with B symptoms, HBV and HCV were positive in 8/70 and 2/70 patients, respectively; no HIV-positive patients were observed. The 2 HCV-positive patients did not receive eradication therapy before BR. One patient was HCV antibody-positive but HCV RNA negative; the other had low viraemia, bone marrow involvement and a wide thigh skin lesion with infiltration of semitendinous muscle, so it was decided to administer BR and to give HCV eradication therapy subsequently.
Overall, SNPs in IL2 (rs 2069762), CXCL8 (rs 4073), MTHFR (rs 1801131) and IL10 (rs1800890 and rs 10494879) were observed in 26, 22, 38 and 6 patients, respectively; while the other investigated genes (VEGFA, rs3025039 and CFH, rs1065489) were wild type for all cases.
Response to treatment and toxicity
Response to treatment and toxicity are represented in Table II . Overall, 51/69 patients (73Á9%) achieved a CR, with an ORR of 97Á1%, while 2 cases (2Á9%) experienced stable or progressive disease (PD). Non-responders were represented by FL patient who was refractory to two previous therapies and received idelalisib and a SLL patient who received ibrutinib; both achieved a durable CR. Response rates were comparable for all different histologies; remarkably, all MCL patients obtained a CR.
After a median follow-up of 24 months, 67/69 patients were alive and 2 had died, 1 from PD and the other from cardiac failure while in CR. Nine patients without events but with a follow-up <6 months were excluded from survival analysis. Median PFS and OS were not reached for the 61 evaluable patients; 5 patients relapsed (1/45 previously untreated and 4/16 relapsed/refractory) and the estimated 3- year PFS was 66Á7% (Fig 1) . These patients were treated with fludarabine-based therapy (3 cases, 1/3 was splenectomized), rituximab plus cyclophosphamide, vincristine, prednisone (1 case) and BR; remarkably, the patient receiving BR achieved a second CR. Overall, 52/70 (74Á3%) patients completed the treatment, while 18/70 (25Á7%) had treatment interruptions; early interruptions were due to toxicity in chemosensitive patients (5 cases), inefficacy at intermediate evaluation (2 cases), relapse of lung cancer (1 case, successfully treated with lobectomy), investigator's choice after achieving CR in localized diseases (7 gastric MALT lymphoma cases), or patient choice (3 elderly chemosensitive cases). Overall toxicity included grade 3-4 neutropenia (24/70 patients, treated with G-CSF), infections (21/70 patients; 1/21 grade 3 that required hospitalization), grade 1-2 nausea (21/70 patients) and skin rash (26/70 patients; 2/26 grade 3). No grade 3-4 anaemia or thrombocytopenia were reported.
SNPs association with treatment efficacy and toxicity
In our cohort, a significant difference in the distribution of studied SNPs among patients achieving CR or PR was not observed. This finding was confirmed when we separately analysed patients with different histologies.
Moreover, we have observed a lack of association between the studied polymorphisms, relapse rate and PFS.
Interestingly, we demonstrated a highly significant association between a SNP in IL2 (rs2069762) and the onset of skin rash (P = 0Á0001; Table III ). The complete genotyping analysis of IL2 SNP (rs2069762), according to histology and onset of skin rash, is summarized in Table IV . A TTvsGT/GG analysis was performed as opposed to a three-way test because of the limited number of GG patients (no patients with LPL, MCL and SLL were GG) and according to previously published data (Cerhan et al, 2007; Kube et al, 2008; Guti errez-C ıvicos et al, 2016) . Table IV also reports the three-way 
CI, confidence interval; CR, complete response; MAF, minor allele frequency; OR, odds ratio; SNP, single nucleotide polymorphism.
Bold value: not significant. analysis for the whole cohort, FL and MZL patients, with comparable results. Among different histologies, this finding was confirmed for FL (P = 0Á001), LPL (P = 0Á03) and MCL (P = 0Á02), while an association was not observed for SLL (only TT cases) and MZL. OR was 75 for FL (95% CI 3Á9221-1434Á1920), 65 for LPL (95% CI 0Á9918-4259Á7972), 21 for MCL (95% CI 0Á639-690Á0306) and 4Á33 for MZL (odds ratio 4Á33, 95% CI 0Á7995-23Á4877) (Fig 2) .
SNPs and Outcome in NHL Receiving
Discussion
In this study we observed that (i) the BR regimen has high efficacy and manageable toxicity for iNHL patients and MCL patients not eligible for high-dose therapy, (ii) the studied polymorphisms did not influence treatment outcome, (iii) a SNP in IL2 (rs2069762) was associated with the onset of skin rash.
iNHL and MCL showed a highly variable clinical behaviour, most patients were chemosensitive but tended to relapse over time (Dreyling et al, 2013; Tarella et al, 2015) . Little information is available regarding biological variables that could influence treatment efficacy and toxicity.
A cytokine-mediated connection that involves innate immunity, inflammation and cancer was reported, that strongly depends on different mediators released by both host inflammatory cells and cancer cells. In these processes, cytokines demonstrated the capability to both promote tumour progression by chronic inflammation and exert antitumour effects (Lin & Karin, 2007) .
Cerhan et al (2007) tested, in 278 FL cases, the hypothesis that host immune gene polymorphisms could influence the survival of FL patients. They studied genes involved in cytokine function and regulation, prioritising those already associated with NHL prognosis and a MAF more than 5% to avoid selection bias. Using rigorous statistical criteria, they identified 9 SNPs in 9 genes and created a SNP score (Cerhan et al, 2007) . The patients received chemotherapy (63%), observation (25%) or radiotherapy (12%). After a median follow-up of 59 months they observed that SNPs in CXCL8 (rs4073), IL2 (rs2069762), IL12B (rs3212227) and IL1RN (rs454078) were strong survival biomarkers; moreover, the number of deleterious genes was associated with OS (P = 0Á001) and this association was strengthened when the SNP score was combined with clinical and demographic variables (P < 0Á001) (Cerhan et al, 2007) . This study lacks of treatment information and was performed before the widespread use of rituximab-based regimens, but it was the pivotal study that showed SNPs could influence FL prognosis.
Since then, pharmacogenomics has gained a growing role in lymphoid malignancies and SNPs have been associated with the efficacy of multiple drugs (Johnson et al, 2014) . Moreover, many studies demonstrated that polymorphisms in immune function genes could play a role in the prediction of NHL prognosis (Cerhan et al, 2007; Kube et al, 2008; Aschebrook-Kilfoy et al, 2012; Wr obel et al, 2013) . The prognostic role of SNPs in the complement pathway was examined in a study that enrolled 107 FL patients (Charbonneau et al, 2012) . Genotyping analysis found that intronic and a coding non-synonymous SNPs in the gene encoding CFH TT (n = 6) 5 1 0Á001 0Á001 GT (n = 14) 1 13 GG (n = 2) / 2 Marginal zone lymphoma (n = 28) TT (n = 9) 6 3 n.s. n.s.
n.s., not significant. (the main negative regulator molecule in the alternative pathway) were associated with event-free survival (EFS); rituximab was administered to 35/107 cases (33%) (Charbonneau et al, 2012) . Given that cytokines control lymphoid differentiation and contribute to T-helper (Th) immune response, polymorphisms in cytokine genes could cause a shift in the Th1/Th2 response and contribute to NHL pathogenesis and progression (Cerhan et al, 2007; Aschebrook-Kilfoy et al, 2012) . In an important multicentre study including various NHL subtypes, 117 FL patients were enrolled; 7 SNPs including CCR2 (rs1799864), IFNGR1 (rs3799488), IL4R (rs1801275), CXCL8 (rs4073 and rs2227307), MIF (rs755622) and SELE (rs5361) were related to an increased risk of death, even when the treatment schedule did not include rituximab (AschebrookKilfoy et al, 2012) . The effect of IL10 polymorphisms on aggressive NHL outcome was studied in 500 patients obtained from NHL-B1 and NHL-B2 trials. Decreased OS was observed in patients characterized by IL10 -7400DelDel expression compared to other genotypes (3-year OS 43Á4% vs. 73Á4%, P = 0Á004); a significant association between IL10 -597AC and grade 3-4 leucopenia was reported for heterozygous cases (Kube et al, 2008) .
Most of these studies were designed in the pre-rituximab era, treatment schedules were heterogeneous, often not specified and did not include bendamustine. To our knowledge, only 1 study, focused on CLL cells, demonstrated that polymorphic variants of the human organic cation transporter 1 (hOCT1), a known mediator of the uptake and cytotoxicity of bendamustine, could determine impaired drug cytotoxicity in HEK293 cells (Arimany-Nardi et al, 2015) . Moreover, a possible correlation between SNPs and treatment toxicity has rarely been mentioned. According to these findings, we decided to investigate some previously analysed SNPs in genes involved in immune function and angiogenesis in our cohort of 70 homogeneously treated patients receiving the BR regimen.
We confirm high treatment efficacy and manageable toxicity of BR; CR rate and PFS are comparable to literature data (Rummel et al, 2013; Flinn et al, 2014) . After a median follow-up of 24 months, the SNPs investigated in our study did not show any correlation with treatment response, PFS or OS. We did not confirm literature data but this could be due to the relatively short follow-up period for iNHL patients and the limited number of observed events.
Remarkably, in our study we demonstrated a highly significant association between the IL2 SNP (rs2069762) and the onset of treatment-related skin rash, a well-known and frequent adverse event of bendamustine. To our knowledge, only a few reports, focused on aggressive NHL receiving R-CHOP, observed a correlation between SNPs and treatment toxicity (Gustafson et al, 2014; Jordheim et al, 2015) .
IL2 plays a crucial role in T cell-mediated immune response, thus exerting an anti-tumour activity. It influences T lymphocytes activation-induced cell death and improves regulatory T cell activity, thus contributing to the elimination of self-reactive cells. Moreover, it could induce the production of suppressive T cells and a decrease in the number of memory T cells expressing CD8. The identified SNP (rs2069762) is in the promoter region of IL2 and the expression of the T allele results in decreased IL2 production, shifting the Th1/Th2 balance of immune response towards the Th2 subtype, as frequently reported in atopic subjects (Christensen et al, 2006) . The expression of the T allele of this SNP has been linked with predisposition to allergic diseases (Christensen et al, 2006) , asthma and atopic eczema in a Danish cohort; although it is not associated with cancer risk, it could represent a possible mechanism to understand the pathophysiology of bendamustine-related skin rash (Christensen et al, 2006; Wang et al, 2015) .
In conclusion, we confirm the treatment efficacy and manageable toxicity of BR regimen for iNHL patients and MCL patients not suitable for high-dose therapy, although the median follow-up of our cohort is too short for a conclusive survival analysis.
The novelty of our study is represented by the finding of a possible correlation between the IL2 SNP (rs2069762), which causes decreased IL2 production and bendamustine-related skin toxicity. We suggest it could represent a promising research field to better understand the heterogeneity in treatment tolerance frequently observed with the BR regimen.
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